What's Going On With Adaptive Biotechnologies Shares Tuesday?

Benzinga_recent_news01-13

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares are trading flat. The stock gained premarket on possible continued momentum after the company announced preliminary fourth-quarter and fiscal-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603333186?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/13/benzingaai2023-stock-market-trading-setu.png?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-13 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603333186","market":"us","top_or_hot":-1,"title":"What's Going On With Adaptive Biotechnologies Shares Tuesday?","media":"Benzinga_recent_news","content":"<div>\n<p>Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares are trading flat. The stock gained premarket on possible continued momentum after the company announced preliminary fourth-quarter and fiscal-...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/01/49875322/whats-going-on-with-adaptive-biotechnologies-shares-tuesday\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going On With Adaptive Biotechnologies Shares Tuesday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going On With Adaptive Biotechnologies Shares Tuesday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-13 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/01/49875322/whats-going-on-with-adaptive-biotechnologies-shares-tuesday><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares are trading flat. The stock gained premarket on possible continued momentum after the company announced preliminary fourth-quarter and fiscal-...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/01/49875322/whats-going-on-with-adaptive-biotechnologies-shares-tuesday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADPT","symbol_name":"Adaptive Biotechnologies Corp","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49875322/whats-going-on-with-adaptive-biotechnologies-shares-tuesday","article_id":"2603333186","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/13/benzingaai2023-stock-market-trading-setu.png?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49875322/whats-going-on-with-adaptive-biotechnologies-shares-tuesday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603333186","pubTimestamp":1768315200,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Adaptive shares are trading higher on possible continued momentum after the company announced preliminary fourth-quarter and fiscal-year revenues above estimates.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADPT":"Adaptive Biotechnologies Corp","BK4121":"生命科学工具和服务"},"translate_title":"周二Adaptive Biotechnologies的股票发生了什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":1},"content_text":"Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares are trading flat. The stock gained premarket on possible continued momentum after the company announced preliminary fourth-quarter and fiscal-year revenues above estimates.\nAdaptive reported preliminary, unaudited revenue of approximately $72 million for the fourth quarter of 2025, representing a 51% increase compared to the same period in 2024. Full-year 2025 revenue totaled approximately $277 million, up 55% year over year.\nThe company said minimal residual disease revenue reached approximately $62 million in the fourth quarter and $212 million for the full year, reflecting growth of 54% and 46%, respectively, compared to 2024. Excluding MRD regulatory milestone revenue, full-year MRD revenue increased 45% year over year.\nAdaptive also reported strong growth in clonoSEQ testing volume. Test volume increased 43% to approximately 30,000 tests in the fourth quarter of 2025 compared to the prior-year quarter. For the full year, approximately 105,600 clonoSEQ tests were delivered, representing a 39% increase from 2024.\nAs of Dec. 31, 2025, the company reported cash, cash equivalents, and marketable securities of approximately $227 million, excluding cash held by Digital Biotechnologies, Inc.\nAdaptive Biotechnologies said it plans to release complete fourth-quarter and full-year 2025 financial results during its earnings call in February 2026.\nADPT Price Action: At the time of writing, Adaptive shares are down 0.11% at $18.24, according to data from Benzinga Pro,\nThis illustration was generated using artificial intelligence via Midjourney.\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603333186","isCrawlerRequest":true}